Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity

被引:12
作者
Kawanishi, C
Furuno, T
Onishi, H
Sugiyama, N
Suzuki, K
Matsumura, T
Ishigami, T
Kosaka, K
机构
[1] Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[2] Yokohama City Univ, Sch Med, Dept Internal Med 2, Yokohama, Kanagawa 232, Japan
关键词
CYP2D6; debrisoquine; 4-hydroxylase; neuroleptics; neuroleptic; malignant syndrome; pharmacogenetics; polymorphism; side-effect;
D O I
10.1097/00041444-200010030-00007
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学]; 090102 [作物遗传育种];
摘要
Decreased activity of debrisoquine 4-hydroxylase (CYP2D6), which participates in hepatic metabolism of several frequently used neuroleptics and antidepressants, is inherited as an autosomal recessive trait through polymorphic CYP2D6 gene alleles, In eastern Orientals, a C --> T substitution at nucleotide 188 (Pro34Ser) is primarily responsible for decreased ability to metabolize CYP2D6 substrates. We therefore studied a possible association between neuroleptic malignant syndrome (NMS) and the C188T mutation. We examined the frequency of the C188T mutation by polymerase chain reaction and restriction fragment length polymorphism analysis in 36 Japanese patients previously diagnosed with NMS and 107 neuroleptic-treated schizophrenic patients with no NMS history. The C188T allele frequency was 0.417 in NMS patients and 0.463 in patients without NMS. No significant allele or genotype associations were observed. We cannot conclude that low CYP2D6 activity genotype causes susceptibility to NMS in Japanese patients. Psychiatr Genet 10:145-147 (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:145 / 147
页数:3
相关论文
共 16 条
[1]
THE CYTOCHROME-P450 CYP2D6 ALLELIC VARIANT CYP2D6J AND RELATED POLYMORPHISMS IN A EUROPEAN POPULATION [J].
ARMSTRONG, M ;
FAIRBROTHER, K ;
IDLE, JR ;
DALY, AK .
PHARMACOGENETICS, 1994, 4 (02) :73-81
[2]
GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS [J].
DAHL, ML ;
YUE, QY ;
ROH, HK ;
JOHANSSON, I ;
SAWE, J ;
SJOQVIST, F ;
BERTILSSON, L .
PHARMACOGENETICS, 1995, 5 (03) :159-164
[3]
Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[4]
NEUROLEPTIC MALIGNANT SYNDROME - OBSERVATIONS ON ALTERED CONSCIOUSNESS [J].
DEUSCHL, G ;
OEPEN, G ;
HERMLE, L ;
KINDT, H .
PHARMACOPSYCHIATRY, 1987, 20 (04) :168-170
[5]
ITOH H, 1977, FOLIA PSYCHIAT NEU J, V31, P565
[6]
[7]
Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia [J].
Kapitany, T ;
Meszaros, K ;
Lenzinger, E ;
Schindler, SD ;
Barnas, C ;
Fuchs, K ;
Sieghart, W ;
Aschauer, HN ;
Kasper, S .
SCHIZOPHRENIA RESEARCH, 1998, 32 (02) :101-106
[8]
Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome [J].
Kawanishi, C ;
Shimoda, Y ;
Fujimaki, J ;
Onishi, H ;
Suzuki, K ;
Hanihara, T ;
Sugiyama, N ;
Kosaka, K .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 160 (01) :102-104
[9]
LAZARUS AL, 1991, CLIN GENET, V39, P65
[10]
Genetic polymorphism and Parkinson's disease in Taiwan: Study of debrisoquine 4-hydroxylase (CYP2D6) [J].
Lo, HS ;
Chen, CH ;
Hogan, EL ;
Kao, KP ;
Wang, VC ;
Yan, SH .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1998, 158 (01) :38-42